APLS FY 2025 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.0B+28.5% YoY

Gross Profit

$902M89.8% margin

Operating Income

$55M5.5% margin

Net Income

$22M2.2% margin

EPS (Diluted)

$0.18

Cash Flow

Operating Cash Flow

$45M

Free Cash Flow

$45M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$705M

Stockholders' Equity

$370M

Cash & Equivalents

$468M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.0B	$781M	+28.5%
Gross Profit	$902M	$664M	+35.8%
Operating Income	$55M	-$165M	+133.6%
Net Income	$22M	-$198M	+111.3%